标题
RTK Inhibitors in Melanoma: From Bench to Bedside
作者
关键词
-
出版物
Cancers
Volume 13, Issue 7, Pages 1685
出版商
MDPI AG
发表日期
2021-04-02
DOI
10.3390/cancers13071685
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
- (2020) Emerson Soares Veloso et al. BMC Veterinary Research
- Bevacizumab treatment of meningeal melanoma metastases
- (2020) Trude G. Simonsen et al. Journal of Translational Medicine
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
- (2019) Karwaciak et al. Cancers
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells
- (2019) Senthil R. Kumar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
- (2019) Felicity Newell et al. Nature Communications
- Fibroblast Growth Factor Receptor Signaling in Skin Cancers
- (2019) Malgorzata Czyz Cells
- Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
- (2019) Aasen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
- (2019) Ishani Das et al. Cell Death & Disease
- Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
- (2019) Aleksandra Simiczyjew et al. Frontiers in Pharmacology
- FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR
- (2019) Lei Li et al. BMC CANCER
- Pexidartinib: First Approval
- (2019) Yvette N. Lamb DRUGS
- Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
- (2019) Maria Grazia Atzori et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma
- (2019) Yara Abdou et al. MEDICINE
- Structural basis of the activation of type 1 insulin-like growth factor receptor
- (2019) Jie Li et al. Nature Communications
- Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
- (2019) Ewelina Dratkiewicz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
- (2018) P G Corrie et al. ANNALS OF ONCOLOGY
- The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells
- (2018) Daniela Dörfel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
- (2018) Julie Delyon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets
- (2018) Jiong Lyu et al. JOURNAL OF PATHOLOGY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway
- (2018) Xuefeng Wan et al. Molecular Medicine Reports
- Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
- (2018) Ewelina Dratkiewicz et al. Oncotarget
- Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model
- (2018) István Kenessey et al. MELANOMA RESEARCH
- Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study
- (2018) Xiaoting Wei et al. ONCOLOGY RESEARCH
- Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
- (2018) Josip Skoko et al. BMC CELL BIOLOGY
- HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
- (2018) Federica Papaccio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma
- (2018) Meredith McKean et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma
- (2017) Jennifer D. Hintzsche et al. MELANOMA RESEARCH
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- NRAS-mutant melanoma: current challenges and future prospect
- (2017) Eva Muñoz-Couselo et al. OncoTargets and Therapy
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
- (2017) Felicity MacDonald et al. Frontiers in Pharmacology
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
- (2017) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma
- (2017) L. A. Fecher et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
- (2017) Helena A. Yu et al. Journal of the National Comprehensive Cancer Network
- Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation
- (2016) Lucia Kucerova et al. BMC CANCER
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
- (2016) Jin S. Im et al. PLoS One
- The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
- (2015) A P Algazi et al. BRITISH JOURNAL OF CANCER
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma
- (2015) Elizabeth I. Buchbinder et al. CANCER
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
- (2015) R. D. Carvajal et al. CLINICAL CANCER RESEARCH
- Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
- (2015) Hui-Hui Cao et al. Molecular Cancer
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers
- (2015) K. T. Flaherty et al. ONCOLOGIST
- Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)
- (2015) S. J. Lee et al. ONCOLOGIST
- A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma
- (2015) Tejaswi V. Mudigonda et al. Pigment Cell & Melanoma Research
- PTEN regulates IGF-1R-mediated therapy resistance in melanoma
- (2015) Jun Wang et al. Pigment Cell & Melanoma Research
- The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids
- (2015) George Hedger et al. Scientific Reports
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Phenotype Switching in Melanoma: Implications for Progression and Therapy
- (2015) Frederic Zhentao Li et al. Frontiers in Oncology
- Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
- (2015) Elisabetta Vergani et al. NEOPLASIA
- Targeting c-Met in melanoma
- (2014) Deven Etnyre et al. CANCER BIOLOGY & THERAPY
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- Different Epidermal Growth Factor (EGF) Receptor Ligands Show Distinct Kinetics and Biased or Partial Agonism for Homodimer and Heterodimer Formation
- (2014) Jennifer L. Macdonald-Obermann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma
- (2014) Suthee Rapisuwon et al. MELANOMA RESEARCH
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
- (2014) Leonard Appleman et al. OncoTargets and Therapy
- Receptor Tyrosine Kinases: Legacy of the First Two Decades
- (2014) J. Schlessinger Cold Spring Harbor Perspectives in Biology
- Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling
- (2013) Hui-Hui Cao et al. BIOCHEMICAL PHARMACOLOGY
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Characterization of KIT mutation in melanoma
- (2013) Chi-Yuan Tzen et al. Dermatologica Sinica
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts
- (2013) Jon-Vidar Gaustad et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells
- (2013) Jason R. Todd et al. Pigment Cell & Melanoma Research
- Why is melanoma so metastatic?
- (2013) Russell R. Braeuer et al. Pigment Cell & Melanoma Research
- Progress in cancer therapy targeting c-Met signaling pathway
- (2012) Kyung Hee Jung et al. ARCHIVES OF PHARMACAL RESEARCH
- Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts
- (2012) Jon-Vidar Gaustad et al. BMC CANCER
- Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
- (2012) W. Wang et al. CLINICAL CANCER RESEARCH
- Sunitinib Therapy for Melanoma Patients withKITMutations
- (2012) David R. Minor et al. CLINICAL CANCER RESEARCH
- The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
- (2012) Fabiola Cecchi et al. Current Signal Transduction Therapy
- EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling
- (2012) Kristy J. Wilson et al. GROWTH FACTORS
- Targeting Oncogenic Drivers and the Immune System in Melanoma
- (2012) Grant A. McArthur et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model
- (2012) Anamika Bose et al. MELANOMA RESEARCH
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling
- (2012) JIANGHONG WU et al. Oncology Letters
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
- (2012) Matthew A. Held et al. Cancer Discovery
- EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?
- (2012) Brian P. Pollack OncoImmunology
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
- (2011) A P Algazi et al. BRITISH JOURNAL OF CANCER
- Mechanism of action of the multikinase inhibitor Foretinib
- (2011) Maeva Dufies et al. CELL CYCLE
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Association of activated c-Met with NRAS-mutated human melanomas
- (2011) Chandrani Chattopadhyay et al. INTERNATIONAL JOURNAL OF CANCER
- Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
- (2011) Jin Hyun Cho et al. INVESTIGATIONAL NEW DRUGS
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
- (2011) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
- (2011) Valerie P. Grignol et al. JOURNAL OF IMMUNOTHERAPY
- A phase II study of gefitinib in patients with metastatic melanoma
- (2011) Sapna P. Patel et al. MELANOMA RESEARCH
- Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
- (2011) K. Tworkoski et al. MOLECULAR CANCER RESEARCH
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- A phase 2 trial of dasatinib in advanced melanoma
- (2010) Harriet M. Kluger et al. CANCER
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
- (2010) I. Kenessey et al. CURRENT CANCER DRUG TARGETS
- IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways
- (2010) Wu-Guo Deng et al. MELANOMA RESEARCH
- Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model
- (2010) C. Cullinane et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
- (2009) Natalia Jura et al. CELL
- Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
- (2009) N. Schicher et al. CLINICAL CANCER RESEARCH
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration
- (2009) David Labbé et al. JOURNAL OF NUTRITION
- Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
- (2009) Jade Homsi et al. MELANOMA RESEARCH
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
- Activate and resist: L576P-KIT in GIST
- (2009) E. Conca et al. MOLECULAR CANCER THERAPEUTICS
- Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
- (2009) S. E. Woodman et al. MOLECULAR CANCER THERAPEUTICS
- Ligand-Stimulated VEGFR2 Signaling is Regulated by Co-Ordinated Trafficking and Proteolysis
- (2009) Alexander F. Bruns et al. TRAFFIC
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
- (2009) Doris R. Siwak et al. Journal of Oncology
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- (2008) K B Kim et al. BRITISH JOURNAL OF CANCER
- Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)
- (2008) S. R. Moore et al. CLINICAL CANCER RESEARCH
- Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
- (2008) H. van Cruijsen et al. CLINICAL CANCER RESEARCH
- Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
- (2008) X. Jiang et al. CLINICAL CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24
- (2008) Suhendan Ekmekcioglu et al. CYTOKINE
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib
- (2008) Navratna Vajpai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
- (2008) Alex J Eustace et al. Journal of Translational Medicine
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- IGF1 Promotes Resistance to Apoptosis in Melanoma Cells through an Increased Expression of BCL2, BCL-X(L), and Survivin
- (2007) Caroline Hilmi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started